Hyaluronan-enriched Medium and Euploid Blastocyst Transfers

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ART Fertility Clinics LLC

Criteria

Inclusion Criteria:

• All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.

• Rank of randomization based on embryo quality.

• Only hormonal replacement theraphy (HRT) cycle regimen.

• Women aged 18 years to 46 years.

• Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.

• All sperm samples.

• BMI between 18 and 35.

Exclusion Criteria:

• FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).

• FET cycles with mosaic / aneuploid blastocysts.

• FET cycles with unknown outcome.

• FET cycles with Day 6 or Day 7 biopsied blastocysts.

• FET with patients' endometrium preparation with treatments other than HRT.

• FET where PGT-A was performed for gender selection.